Heidi Health vs Owkin
Detailed side-by-side comparison to help you choose the right tool
Heidi Health
🟢No CodeHealthcare AI
a clinical AI assistant for healthcare documentation, encounter notes, follow-up letters, and clinician workflow support.
Was this helpful?
Starting Price
CustomOwkin
Healthcare AI
Owkin is a full-stack AI biotech company using federated learning to train machine learning models on hospital data without centralizing patient records. Founded in 2016 and headquartered in Paris, Owkin has raised over $300M in funding, secured a strategic partnership with Sanofi valued at over $180M, and developed MSIntuit CRC—an FDA-cleared AI diagnostic for detecting microsatellite instability in colorectal cancer from standard pathology slides. The company operates the MOSAIC federated learning platform across 15+ academic medical centers worldwide and offers the K Pro AI Scientist for pharma decision-making across clinical trial, patient, and portfolio decisions.
Was this helpful?
Starting Price
CustomFeature Comparison
Scroll horizontally to compare details.
Heidi Health - Pros & Cons
Pros
- ✓Purpose-built for clinical documentation rather than generic meeting notes
- ✓Public site shows healthcare-specific compliance and specialty resources
- ✓Useful fit for reducing after-hours charting when clinicians retain final review
- ✓Free access call-to-action lowers initial trial friction
Cons
- ✗Static pricing details were not extractable from the fetched pricing page
- ✗Healthcare teams still need clinician review, consent language, and privacy due diligence
- ✗EHR integration depth and regional data handling must be verified before rollout
- ✗Ambient scribes can fail on accents, interruptions, multi-speaker visits, and medication details
Owkin - Pros & Cons
Pros
- ✓Unique federated learning architecture via MOSAIC enables training on real-world hospital data without centralizing patient records, providing access to more diverse and representative datasets than competitors
- ✓FDA 510(k)-cleared MSIntuit CRC diagnostic demonstrates regulatory validation, with the ability to triage approximately 30% of colorectal cancer cases without confirmatory molecular testing
- ✓Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration validate platform value for top-tier pharmaceutical companies
- ✓Over 80 peer-reviewed publications in journals like Nature Medicine and The Lancet Digital Health provide strong scientific credibility compared to many AI biotech peers
- ✓Founded in 2016 with over $300M raised and global presence across 7 offices (Paris, London, New York, Cambridge MA, Geneva, Nantes), giving institutional clients confidence in long-term viability
- ✓Multimodal approach combining pathology, genomics, spatial-omics and clinical data captures biological complexity beyond single-modality platforms
Cons
- ✗Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
- ✗Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
- ✗Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
- ✗No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
- ✗Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging
- ✗Regulatory approval for AI diagnostics varies by jurisdiction, and expanding beyond FDA-cleared products to additional cancer types and international markets involves lengthy timelines
Not sure which to pick?
🎯 Take our quiz →Price Drop Alerts
Get notified when AI tools lower their prices
Get weekly AI agent tool insights
Comparisons, new tool launches, and expert recommendations delivered to your inbox.